Abstract: Pruxelutamide is a second-generation androgen receptor antagonist developed by Kintor Pharmaceutical Limited. In response to COVID-19, this drug has dual mechanisms of action, including blocking the entry of SARS-CoV-2 into host cells by down-regulating angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), as well as inhibiting acute inflammation and reducing cytokine-induced tissue/organ damage. Pruxelutamide has therapeutic benefits for patients with mild, moderate or severe COVID-19. The mechanisms and clinical research progress of pruxelutamide in the treatment of COVID-19 were briefly reviewed in this article, aiming to provide ideas for new drug development and clinical treatment of COVID-19.